New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
09:13 EDTELGXEndologix announce preliminary Q4 revenue of about $29.2M, consensus $28.16M
The company anticipates U.S. Revenue to be approximately $23.3M in Q4, representing approximately 20% growth compared to $19.4M for the same quarter in 2011. International revenue is anticipated to be approximately $5.9M in Q4, representing approximately 48% growth compared to $4M for the same quarter in 2011.
News For ELGX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
07:16 EDTELGXEndologix trial results 'highly encouraging,' says Stifel
Subscribe for More Information
November 20, 2014
07:13 EDTELGXCanaccord to hold a forum
Subscribe for More Information
November 18, 2014
11:00 EDTELGXEndologix to host investor meeting
Subscribe for More Information
07:11 EDTELGXEndologix completes patient enrollment in Nellix EVAS FORWARD-IDE clinical trial
Endologix announced that it has completed patient enrollment in the EVAS FORWARD-IDE clinical trial, the company's U.S. pivotal clinical trial designed to evaluate the safety and effectiveness of the Nellix EndoVascular Aneurysm Sealing System for the endovascular repair of infrarenal abdominal aortic aneurysms, or AAA. Primary endpoint analysis results at one-year and beyond will be used to support the company's premarket approval, or PMA, application to the FDA for the Nellix EVAS System. The EVAS FORWARD-IDE clinical trial enrolled 179 patients at 29 centers in the U.S. and Europe. Enrollment under an extended investigation phase is anticipated to begin shortly and will continue during the pivotal trial follow-up period and PMA preparation/review process. Based on current assumptions and timelines, the company anticipates FDA approval of the Nellix System in the U.S. before the end of 2016.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use